Physician in the Loop
For youSign inAsk
Urology ·

AI prostate MRI model matches radiology readings in SCARLET-1; Urocross BPH implant enters U.S. use; TULSA meta-analysis pools 630 patients

A clear specimen cup of pale blue liquid with a urinalysis dipstick leaning in it, one of its square test pads amber, and the screw lid set beside it.
THE SHORT READ

An AI model for prostate MRI performed comparably to radiology readings across external diagnostic and screening data sets from 12 countries, according to the SCARLET-1 study in Radiology. Prodeon Medical began a controlled U.S. release of its temporary Urocross implant for benign prostatic hyperplasia (BPH), and a meta-analysis summarized transurethral ultrasound ablation outcomes.

THE DETAILS
  • AI Oct 13, 2026
    SCARLET-1: AI prostate MRI model performs comparably to radiology readings in external sets from 12 countries
    The study included 22,445 prostate MRI examinations from 21,252 patients, with external testing in 1,974 patients from 20 cities in 12 countries. External area under the curve values were 0.86 in PRIME, 0.89 in STHLM3-MRI and 0.84 in IP1-PROSTAGRAM, and the primary outcome, agreement with standard-of-care diagnoses, met prespecified interchangeability criteria in all three. In PRIME, AI agreement with those diagnoses was 83.0%, versus an estimated 67.4% for an average radiologist, derived from a separate multireader study and adjusted for cancer prevalence. The study measured diagnostic agreement, not patient outcomes.
    Source: Radiology
  • Technology Oct 14, 2026
    Prodeon announces first U.S. commercial case of Urocross Expander, a temporary prostatic implant for BPH
    Prodeon Medical said Oct. 14 that Dr. Tyler McClintock performed the first commercial procedure at The Hospital at Westlake Medical Center in Austin, Texas, beginning a controlled U.S. release. The device, cleared by the Food and Drug Administration in March 2026, is placed in the prostatic urethra through a flexible cystoscope and retrieved after six months. In the Expander-2 trial of 240 men at 23 U.S. and Canadian sites, about 74% of treated patients had at least a 30% improvement in symptom score at 12 months, with no device- or procedure-related serious adverse events, according to Urology Times.
    Sources: Prodeon Medical, Urology Times
  • Research Oct 12, 2026
    Meta-analysis of 630 patients reports 70% one-year recurrence-free survival after primary TULSA for prostate cancer
    The BJU International review pooled 12 studies of MRI-guided transurethral ultrasound ablation (TULSA), in which 563 patients had primary treatment. Pooled 12-month survival free of biopsy-proven clinically significant cancer was 70% (95% CI 50 to 84) after primary TULSA and 80% (95% CI 66 to 89) after salvage TULSA; pad-free continence was 90%, preserved erectile function 81% and grade 3 adverse events 6%. The authors said evidence on long-term oncologic control is lacking and that salvage studies recorded relatively high incontinence rates.
    Source: BJU International
  • AI Oct 16, 2026
    Mayo Clinic AI model identifies sacral anatomy and leads on fluoroscopy during sacral neuromodulation
    Mayo Clinic urologists trained segmentation networks on fluoroscopic images from sacral neuromodulation device placements done from November 2017 to August 2022. On test images, expert review rated anatomic segmentations acceptable in 97% (35 of 36) of anteroposterior and 93% (40 of 43) of lateral images, and electrode segmentation reached a Dice score of 0.889. The authors said further validation is needed before clinical implementation.
    Source: Urology

The weekly innovation roundup for urology, published every Sunday for the week before; every item links to its sources. Latest urology news · All specialties